Assessment of Renal Function in Egyptian HCV Patients Treated with Combination Therapy of Sofosbuvir and Daclatasvir

BACKGROUND: According to the most recent Egyptian demographic health census, estimated Hepatitis C virus (HCV) prevalence in 15–59 age range was 14.7%. Globally, incidence of renal impairment HCV-positive individuals is 40% higher than HCV-negative patients. HCV-induced can from mild-to-severe, and it frequently complicates treatment outcome HCV infection. AIM: This study aimed explore changes function patients treated with a combination Sofosbuvir (SOF) Daclatasvir (DCV). METHODOLOGY: Six hundred eleven chronic SOF-DCV were enrolled. Patients classified into three groups according their baseline function: unimpaired group (estimated glomerular filtration rate [eGFR] ≥ 90 ml/min/1.73 m2), mildly impaired (eGFR ≥60–89 moderately ≥30–59 m2). Every month during at 24 weeks after (sustained virological response 24), eGFR level evaluated. RESULTS: Our findings indicated that significantly increased (p < 0.001) all but subsequent decline documented 6 months treatment. Multivariate analysis identified (<90 m2, p anemia as independent risk factors for deterioration end CONCLUSION: Clinical physicians should closely monitor SOF-DCV. Furthermore, therapy prior be recommended.